Back to Search Start Over

Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial.

Authors :
Dalziel, Stuart R
Walker, Natalie K
Parag, Varsha
Mantell, Colin
Rea, Harold H
Rodgers, Anthony
Harding, Jane E
Source :
Lancet. 5/28/2005, Vol. 365 Issue 9474, p1856-1862. 7p. 5 Charts.
Publication Year :
2005

Abstract

Summary Background Antenatal betamethasone treatment is widely used for the prevention of neonatal respiratory distress syndrome in preterm infants and substantially reduces neonatal mortality and morbidity. Fetal exposure to excess glucocorticoids has been proposed as one of the core mechanisms of the fetal origins of adult disease hypothesis. We assessed whether antenatal exposure to betamethasone for the prevention of neonatal respiratory distress syndrome affects cardiovascular risk factors at 30 years of age. Methods We followed up at age 30 years 534 individuals whose mothers participated in a double-blind, placebo-controlled, randomised trial of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome. Mothers received two doses of betamethasone or placebo given by intramuscular injection 24 h apart. Follow-up assessments included anthropometry; measurement of blood pressure, blood lipids (after overnight fasting), and early morning cortisol levels; and a 75 g oral glucose tolerance test. Findings There were no differences between those exposed to betamethasone and to placebo in body size, blood lipids, blood pressure, plasma cortisol, prevalence of diabetes, or history of cardiovascular disease. After a 75 g oral glucose tolerance test, participants exposed to betamethasone had higher plasma insulin concentrations at 30 min (60·5 vs 52·0 mIU/L; ratio of geometric means 1·16 [95% CI 1·03 to 1·31], p=0·02) and lower glucose concentrations at 120 min (4·8 vs 5·1 mmol/L; difference -0·26 mmol/L [-0·53 to 0·00], p=0·05) than did those exposed to placebo. Interpretation Antenatal exposure to betamethasone might result in insulin resistance in adult offspring, but has no clinical effect on cardiovascular risk factors at 30 years of age. Thus, obstetricians should continue to use a single course of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01406736
Volume :
365
Issue :
9474
Database :
Academic Search Index
Journal :
Lancet
Publication Type :
Academic Journal
Accession number :
17148151
Full Text :
https://doi.org/10.1016/S0140-6736(05)66617-2